^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    GeneseeqPrime™HRD

    Company:
    Geneseeq
    Type:
    CE Marked
    Related tests:

    Details

    Evidence
    News
    GeneseeqPrime™HRD is a next-generation sequencing-based laboratory developed test that analyzes homologous recombination deficiency (HRD)-related genomic instabilities through a genome-wide analysis approach. It also detects genomic alterations in 437 cancer-relevant genes, including BRCA1/2 and other homologous recombination repair (HRR)-relevant genes.
    Cancer:
    Solid Tumor
    Gene:
    BRCA1 (Breast cancer 1, early onset), BRCA2 (Breast cancer 2, early onset), HRD (Homologous Recombination Deficiency), MSI (Microsatellite instability), TMB (Tumor Mutational Burden)
    Method:
    Next-Generation Sequencing (NGS)
    Approvals
    Date
    Cancer
    Gene
    Drug
    By
    08/22/23
    ST
    -
    CE